All In Biotech

Drug Trial Radar · NCT02990481

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Mar 6, 2017

Primary completion

Sep 16, 2019

Study completion Sep 16, 2019

Sponsor

Lead sponsor
Toray Industries, IncIndustry
Sponsor type
Industry
First posted
Dec 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies

Conditions

  • Locally Advanced or Metastatic Solid Carcinomas
  • Colon Cancer
  • Cholangiocarcinoma

Interventions

  • TRK-950Biological

    Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle

  • TRK-950Biological

    Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle

  • TRK-950Biological

    Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventTime frame: through study completion, an average of 1 year
  2. CTCAE version 4.03Time frame: through study completion, an average of 1 year
  3. Blood pressure (mmHg)Time frame: through study completion, an average of 1 year
  4. Heart rate (bpm)Time frame: through study completion, an average of 1 year
  5. Respiratory rate (bpm)Time frame: through study completion, an average of 1 year
  6. Temperature (°F or °C)Time frame: through study completion, an average of 1 year
  7. Weight (lbs/kg)Time frame: through study completion, an average of 1 year
  8. Height (inches/cm)Time frame: through study completion, an average of 1 year
  9. Karnofsky performance statusTime frame: through study completion, an average of 1 year
  10. ElectrocardiogramTime frame: through study completion, an average of 1 year
  11. Clinical laboratory testsTime frame: through study completion, an average of 1 year

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • Centre Léon Bérard

    Lyon, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.